Note that, human clinical study results for the 18F-BMT-986229 PET tracer within the prospective ADAPT-IT unresectable melanoma trial were recently disclosed and demonstrated a good safety and tolerability, while PD-L1 positivity by PET imaging at baseline appeared to be associated with early efficacy from nivolumab + ipilimumab in this small patient cohort [31]. This evidence concerns the gene CD274 and melanoma.